Anavex Life Sciences Corp (AVXL)

[boi568]

I find it very hard to believe that the FDA will require an entirely new Phase 3 AD trial if the 2b/3 shows it met its efficacy endpoints, as announced, and is safe. The FDA's mission is to promote and protect the public health, and putting off for several years a safe and effective AD medication that outperforms the SOC is destructive to that mission and, I'd argue, a violation of medical ethics as well.

More likely would be an AA with a Phase 4, or possibly a decisional delay until the OLE reports out in 2024.